Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: BIIB stock price vs PACB: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at PACB's multiple
Needs PACB P/E.
Implied fair value · at BIIB's multiple
Needs Annual EPS is negative, BIIB P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
13 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BIOGEN INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Pacific Biosciences of California, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PFIZER INC
BIIB vs PFE
JOHNSON & JOHNSON
BIIB vs JNJ
AMGEN INC
BIIB vs AMGN
ELI LILLY & Co
BIIB vs LLY
Natera, Inc.
BIIB vs NTRA
ILLUMINA, INC.
BIIB vs ILMN
THERMO FISHER SCIENTIFIC INC.
BIIB vs TMO
AGILENT TECHNOLOGIES, INC.
BIIB vs A
DANAHER CORP /DE/
BIIB vs DHR
REVVITY, INC.
BIIB vs RVTY
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe BIIB can sustain its 28.7% operating margin and 13.0% ROIC while remaining within its historical valuation band, then hold or accumulate selectively because the stock is only modestly above the PACB-based implied value and is backed by much stronger profitability than PACB.
BIIB's current price of $202.95 is 9.8% above the PACB-based implied value of $183.15, suggesting a modest premium rather than a deep valuation gap. The stock sits within its historical band of $182.66 to $223.25 and above the DCF range of $133.03 to $179.98, so valuation signals are mixed.
Supporting Metrics
